Xyotax (CT-2103) : Cell Therapeutics, Inc. : Paclitaxel conjugate

Xyotax (paclitaxel poliglumex - PPX)/carboplatin vs paclitaxel/carboplatin for Treatment of Chemotherapy Naive Patients with Advanced NSCLC and Poor Performance Status (PS2) (ASCO)
Abstract of a phase III randomized trial presented at the 2005 ASCO annual meeting that demonstrated Xyotax (paclitaxel poliglumex - PPX)/carboplatin provides similar efficacy with less toxicity as compared to paclitaxel/carboplatin for first-line treatment of poor performance (PS2) patients with advanced NSCLC. [5/05]

Pivotal Trials Demonstrate Xyotax Produces Equivalent Survival While Reducing Serious Side Effects in the Treatment of NSCLC (Cell Therapeutics, Inc.)
Press release announcing the results of two phase III trials in NSCLC designed to determine if Xyotax could increase the overall survival of patients while reducing the serious side effects associated with the treatment of first-line or second-line NSCLC. Both trials demonstrated equivalent survival with significant reductions in serious side effects when compared to either docetaxel or gemcitabine/vinorelbine; although they missed their primary endpoints of superior overall survival. Xyotax is administered in a 10-minute infusion without the need for steroids or other premedications. [5/05]

Xyotax (Cell Therapeutics, Inc)
Manufacturer's description of Xyotax and how it works. Discusses the tolerability and efficacy of Xyotax in preclinical studies. [4/06]

Xyotax (CT-2103) - Recent MEDLINE Abstracts (PubMed)

Xyotax (CT-2103) - Clinical Trials (ClinicalTrials.gov)